[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100573222":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":19,"centralContacts":23,"locations":29,"responsibleParty":55,"collaborators":18,"id":59,"slug":60,"hasResults":61,"nctId":62,"briefTitle":63,"officialTitle":64,"acronym":65,"eligibilityCriteria":66,"healthyVolunteers":61,"sex":67,"minAge":68,"maxAge":69,"enrollmentInfo":70,"targetDuration":18,"studyType":73,"phases":74,"briefSummary":76,"conditions":77,"keywords":18,"overallStatus":32,"whyStopped":18,"lastUpdateSubmitDate":79,"lastUpdatePostDateStruct":80,"startDateStruct":83,"completionDateStruct":84,"leadSponsor":86,"locationsCount":87},{"fullName":5,"class":6},"The First People's Hospital of Yunnan","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Supergraft","EXPERIMENTAL","Hypertransplantation is an innovative treatment plan of Professor Ai Huisheng's team, which uses hematopoietic stem cell transplantation from healthy donors who are haplotype compatible with the patient, and observes the patient's cell reinfusion response, hematopoietic reconstitution, hemoglobin level and blood transfusion, thalassemia clonal clearance, immune reconstitution, endocrine function recovery, gastrointestinal function recovery, as well as the incidence of graft-versus-host disease, infection and other complications after transplantation.",[13],"Other: Supergraft",[15],{"type":6,"name":9,"description":16,"armGroupLabels":17,"otherNames":18},"This study is a prospective, single-center, single-arm clinical study, and it is planned to include 3-5 patients with Eastern Mediterranean major who have no HSCT indication and cannot undergo Eastern Mediterranean gene therapy. The diagnosis of Eastern Mediterranean major was determined by the genotype of Eastern Mediterranean and the clinical manifestations of patients, and patients who met the inclusion criteria were screened and enrolled and received super transplant therapy.",[9],null,[20],{"name":21,"affiliation":5,"role":22},"Yang T Yang, master","PRINCIPAL_INVESTIGATOR",[24],{"name":25,"role":26,"phone":27,"phoneExt":18,"email":28},"Yang tonghua T Yang, master","CONTACT","86-13888555608","ynanblood@aliyun.com",[30],{"facility":31,"status":32,"city":33,"state":34,"zip":35,"country":36,"countryCode":37,"cosmosGeoPoint":38,"geoPoint":43,"contacts":44},"Yunnan First People's Hospital","RECRUITING","Kunming","Yunnan","650000","China","CN",{"type":39,"coordinates":40},"Point",[41,42],102.71833,25.03889,{"lat":42,"lon":41},[45,49,54],{"name":46,"role":26,"phone":47,"phoneExt":48,"email":28},"Yang t hua, Master","+86 13888555608","13888555608",{"name":50,"role":26,"phone":51,"phoneExt":52,"email":53},"hu p Deputy chief physician, Master","+8613987612095","13987612095","hupengkkxx@126.com",{"name":46,"role":22,"phone":18,"phoneExt":18,"email":18},{"type":56,"investigatorFullName":57,"investigatorTitle":58,"investigatorAffiliation":5,"oldNameTitle":18,"oldOrganization":18},"SPONSOR_INVESTIGATOR","Hu Peng","Deputy Chief Physician","100573222","a-clinical-study-of-ultra-transplantation-for-the-treatment-of-major-thalassemia-scheme-100573222",false,"NCT06743477","A Clinical Study of Ultra-transplantation for the Treatment of Major Thalassemia Scheme","Clinical Study Protocol for Ultra-transplantation for the Treatment of Eastern Mediterranean Major","UTTS","Patient inclusion criteria :\n\n* Diagnosed with severe Mediterranean anemia, with no restrictions on alpha and beta types;\n* Age between 7-12 years old, male or female not limited; Weight\\\u003C40kg\n* The patient has or does not have HLA matched or semi matched donors, but unconditionally transplants or refuses to undergo blood stem cell transplantation treatment; And patients who unconditionally or refuse to undergo gene therapy for thalassemia;\n* There are HLA matched or mismatched donors who meet the donor criteria through physical examination;\n* The patient and their family agree to receive super transplantation treatment and sign a written informed consent form before the transplantation trial.\n\n  （2） Exclusion criteria for patients:\n* Psychiatric patients;\n* Participants in clinical trials of other drugs within the past month;\n* There are no suitable HLA mismatched donors available.\n* Other researchers have determined that they are not suitable to participate in this study.\n\n  （3） Supplier screening criteria:\n* HLA typing matches the patient's haplotype\n* KIR configuration\n* NIMA\n* DSA negative\n* Routine physical examination\n* Genetic screening for carriers of thalassemia, mild or no carriers of thalassemia\n* Sign the informed consent form.","ALL","7 Years","12 Years",{"count":71,"type":72},5,"ESTIMATED","INTERVENTIONAL",[75],"NA","Yunnan is a high-incidence area of Eastern Mediterranean (thalassemia) in China, and the treatment cost of thalassemia patients is high, hematopoietic stem cell transplantation (HSCT) is the only means to cure thalassemia, but there are problems in donor screening and the risk of complications. Professor Ai Huisheng's team proposed a new concept of hypertransplantation, which does not require pretreatment and has no risk of GVHD, and animal experiments have shown good efficacy. Under the guidance of Professor Ai, the center plans to carry out clinical research on hypertransplantation and explore safe and effective new therapies for thalassemia.",[78],"Stem Cell Transplantation","2025-08-29",{"date":81,"type":82},"2025-09-02","ACTUAL",{"date":79,"type":72},{"date":85,"type":72},"2026-12-31",{"name":57,"class":6},1]